Publications

For a full list, see PubMed.


1. Miller RE, Ishihara S, Tran PB, Golub SB, Last K, Miller RJ, Fosang AJ, Malfait AM. An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. JCI Insight. 2018;3(6):e95704. [Article]

2. Miller RE, Kim YS, Tran PB, Ishihara S, Dong X, Miller RJ, Malfait AM. Visualization of Peripheral Neuron Sensitization in a Surgical Mouse Model of Osteoarthritis by In Vivo Calcium Imaging. Arthritis Rheumatol. 70:88. 2018. [Pubmed]

3. Malfait AM, Pincus T. Pain in rheumatic diseases. Clin Exp Rheumatol. 35:1. 2017. [Pubmed]

4. Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 35:85. 2017. [Pubmed]

5. Miller RE, Miller RJ. Is cannabis an effective treatment for joint pain? Clin Exp Rheumatol. 35:59. 2017. [Pubmed]

6. Malfait AM. Why we should study pain in animal models of rheumatic diseases. Clin Exp Rheumatol. 35:37. 2017. [Pubmed]

7. Sambamurthy N, Nguyen V, Smalley R, Xiao R, Hankenson K, Gan J, Miller RE, Malfait AM, Dodge GR, Scanzello CR. Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. J Orthop Res. In Press. 2017. [Pubmed]

8. Miller RE, Ishihara S, Bhattacharyya B, Delaney A, Menichella DM, Miller RJ, Malfait AM. Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis. Arthritis Rheumatol. 69:1429. 2017. [Pubmed][Editorial]

9. Miller RE and Malfait AM. Can we target CCR2 to treat osteoarthritis? The trick is in the timing! Osteoarthritis Cartilage. 25:799. 2017. [Pubmed]

10. Malfait AM and Miller RJ. Emerging Targets for the Management of Osteoarthritis Pain. Curr Osteoporos Rep. 14:260. 2016. [Pubmed]

11. Vincent T, Malfait AM. Time to be positive about negative data? Osteoarthritis Cartilage. 25:351. 2017. [Pubmed]

12. Miotla Zarebska J, Chanalaris A, Driscoll C, Burleigh A, Miller RE, Malfait AM, Stott B, Vincent TL. CCL2 and CCR2 regulate pain-related behaviour and early gene expression in post-traumatic murine osteoarthritis but contribute little to chondropathy. Osteoarthritis Cartilage. 25:406-412. 2017. [Pubmed]

13. Miller RE, Block JA, Malfait AM. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr Opin Rheumatol. 29:110-118. 2017. [Pubmed]

14. Tran PB, Miller RE, Ishihara S, Miller RJ, Malfait AM. Spinal Microglial Activation in a Murine Surgical Model of Knee Osteoarthritis. Osteoarthritis Cartilage. 25:718-726. 2017. [Pubmed][Editorial]

15. Miller RE, Tran PB, Ishihara S, Larkin J, Malfait AM. Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. Osteoarthritis Cartilage. 24:299. 2016. [Pubmed]

16. Malfait AM. Osteoarthritis year in review 2015: biology. Osteoarthritis Cartilage. 24:21. 2016. [Pubmed]

17. Miller RE, Belmadani A, Ishihara S, Tran PB, Ren D, Miller RJ, Malfait AM. Damage-Associated Molecular Patterns Generated in Osteoarthritis Directly Excite Murine Nociceptive Neurons through Toll-like Receptor 4. Arthritis & Rheumatology. 67(11):2933-43. 2015. [Pubmed]

18. Miller RE, Tran PB, Obeidat AM, Raghu P, Ishihara S, Miller RJ, Malfait AM. The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain. Current Osteoporosis Reports. 13(5):318-26. 2015. [Pubmed]

19. Malfait AM and Little CB. On the predictive utility of animal models of osteoarthritis. Arthritis Res Ther. 17:225. 2015. [Pubmed]

20. Chen S, Cao P, Dong N, Peng J, Zhang C, Wang H, Zhou T, Yang J, Zhang Y, Martelli EE, Naga Prasad SV, Miller RE, Malfait AM, Zhou Y, Wu Q. PCSK6-mediated corin activation is essential for normal blood pressure. Nature Medicine. 21(9):1048-53. 2015. [Pubmed]

21. Larkin J, Lohr TA, Elefante L, Shearin J, Matico R, Su JL, Xue Y, Liu F, Genell C, Miller RE, Tran PB, Malfait AM, Maier CC, Matheny CJ. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 23(8):1254-66. 2015. [Pubmed]

22. Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: The cytokine connection. Cytokine. 70(2):185-93. 2014. [Pubmed]

23. Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 9(11):654-664. 2013. [Pubmed]

24. Malfait AM, Little CB, McDougall JJ. A commentary on modelling osteoarthritis pain in small animals. Osteoarthritis Cartilage. 21(9):1316-1326. 2013. [Pubmed]

25. Miller RE, Lu Y, Tortorella MD, Malfait AM. Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets. Curr Rheumatol Rep. 15(9):350. 2013. [Pubmed]

26. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, Malfait AM. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. PNAS. 109(50):20602-7. 2012. [Pubmed]

27. Morgen M, Tung D, Boras B, Miller W, Malfait AM, Tortorella MD. Nanoparticles for Improved Local Retention after Intra-Articular Injection into the Knee Joint. Pharmaceutical Research. 30(1):257-68. 2013. [Pubmed]

28. Malfait AM, Seymour AB, Gao F, Tortorella MD, Le Graverand-Gastineau MPH, Wood LS, Doherty M, Doherty S, Zhang W, Arden NK, Vaughn FL, Leaverton PE, Spector TD, Hart DJ, Maciewicz RA, Muir KR, Das R, Sorge RE, Sotocinal SG, Schorscher-Petcu A, Valdes AM, Mogil JS. A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Annals of the Rheumatic Diseases. 71(6):1042-8. 2012. [Pubmed]

29. Nair A, Kanda V, Bush-Joseph C, Verma N, Chubinskaya S, Mikecz K, Glant TT, Malfait AM, Crow MK, Spear GT, Finnegan A, Scanzello CR. Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to TLR-4 and TLR-2 ligands via soluble CD14. Arthritis Rheum. 64(7):2268-77. 2012. [Pubmed]

30. Malfait AM. Modelling pain in post-traumatic osteoarthritis of the knee. Pain. 153(2):257-8. 2012. [Pubmed]

31. Shieh HS, Tomasselli AG, Mathis KJ, Schnute ME, Woodard SS, Caspers N, Williams JM, Kiefer JR, Munie G, Wittwer A, Malfait AM, Tortorella MD. Structure analysis reveals the flexibility of the ADAMTS-5 active site. Protein Sci. 20(4):735-44. 2011. [PubMed]

32. Malfait AM, Ritchie J, Gil AS, Austin JS, Hartke J, Qin W, Tortorella MD, Mogil JS. ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization. Osteoarthritis Cartilage. 18(4):572-80. 2010. [PubMed]

33. Byun S, Tortorella MD, Malfait AM, Fok K, Frank EH, Grodzinsky AJ. Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions. Arch Biochem Biophys. 499(1-2):32-9. 2010. [PubMed]

34. Zack MD, Melton MA, Stock JL, Storer CE, Barve RA, Minnerly JC, Weiss DJ, Stejskal JA, Tortorella MD, Turk JR, Shevlin KM, Malfait AM. Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8). Clin Exp Immunol. 158(2):246-56. 2009. [PubMed]

[Back to Top]